

## Special Issue

# Encephalitis and Viral Infection: Mechanisms and Therapies

### Message from the Guest Editors

This Special Issue offers a platform for researchers to delve into the intricate relationship between neurovirology, encephalitis, and efficient therapies. Neurovirology and encephalitis are complex and often intertwined fields that are informative to the gene therapy field for treating neurologic diseases. In addition, recent advancements in gene therapies have opened new avenues for understanding and treating these encephalitic and neurologic diseases. This Special Issue acts as a bridge, fostering interdisciplinary collaboration and advancing medical knowledge.

We invite original research articles and reviews that contribute to the understanding of the following aspects within the scope of this Special Issue. By bringing together experts from these diverse fields, this Special Issue seeks to foster collaboration, stimulate innovative research, and ultimately contribute to the development of novel therapeutic interventions for neuroviral infections, encephalitis, and neurologic diseases. We welcome manuscripts that explore the intersections of these disciplines, providing a holistic view of the challenges and opportunities in this critical area of biomedical science.

---

### Guest Editors

Dr. Bradley S. Hollidge  
Encephalytics, LLC, New York, NY, USA

Dr. Samantha S. Soldan  
Wistar Institute, Philadelphia, PA, USA

---

### Deadline for manuscript submissions

closed (30 June 2025)



## Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/186591](https://mdpi.com/si/186591)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).